Adial Pharmaceuticals, Inc. (ADIL)

Adial Pharmaceuticals Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Year	Current	2023	2022	2021	2020	2019
Market Capitalization	4	2	6	56	24	25
Market Cap Growth	-83.77%	-60.76%	-89.70%	131.97%	-2.80%	-25.92%
Enterprise Value	-1	-1	2	50	20	18
PE Ratio	-	-0.44	-0.45	-2.89	-2.22	-2.89
PB Ratio	0.72	0.56	1.76	15.98	6.06	3.48
P/FCF Ratio	-0.26	-0.33	-0.52	-4.67	-3.17	-3.92
P/OCF Ratio	-0.26	-0.33	-0.52	-4.69	-3.17	-3.92
EV/EBITDA Ratio	0.39	0.11	-0.14	-2.58	-1.81	-2.11
EV/EBIT Ratio	0.39	0.11	-0.14	-2.58	-1.81	-2.11
EV/FCF Ratio	0.56	0.08	-0.16	-4.18	-2.59	-2.85
Debt / Equity Ratio	-	-	-	0.07	-	-
Debt / EBITDA Ratio	-	-	-	-0.01	-	-
Debt / FCF Ratio	-	-	-	-0.02	-	-
Quick Ratio	8.93	4.33	2.23	2.23	2.92	12.57
Current Ratio	9.48	4.90	2.67	2.37	3.41	14.24
Return on Equity (ROE)	-219.20%	-183.30%	-186.20%	-367.30%	-171.40%	-91.20%
Return on Assets (ROA)	-192.50%	-134.10%	-132.80%	-224.50%	-149.80%	-86.10%
Return on Capital (ROIC)	-105.60%	-168.68%	-331.44%	-512.35%	-274.15%	-115.47%
Earnings Yield	-197.47%	-226.15%	-220.51%	-34.64%	-45.07%	-34.55%
FCF Yield	-139.33%	-300.46%	-193.74%	-21.43%	-31.58%	-25.49%
Buyback Yield / Dilution	-179.05%	-42.25%	-34.69%	-49.15%	-26.50%	-107.01%
Total Shareholder Return	-179.05%	-42.25%	-34.69%	-49.15%	-26.50%	-107.01%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).